

18 January 2024

Genflow Biosciences Plc
("Genflow" or "the Company")

Secures Two Research Grants from Belgium's New Technological Innovation Partnership

The Company (LSE:GNF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process is pleased to announce two significant new research programs in collaboration with Revatis SA and EXO Biologics, backed by substantial non-diluting and non-reimbursable research grants by the Government of Wallonia in Belgium. Funding for the two research programs, as part of the Wallonia Recovery Plan by the Walloon Government in Belgium, will be disbursed annually to the Company, contingent upon Genflow and its collaborators achieving specific, activity-based milestones. Continued receipt of the grants by Genflow is dependent on the parties meeting predefined criteria each applicable year.

Technological Innovation Partnership (ATMP)

The two research programs are a part of a broader innovation partnership that the Walloon Government has launched, dedicated to Advanced Therapy Medicinal Products (ATMPs). The partnership boasts a substantial budget of 81 million euros, a mix of 60% public funding and 40% private contributions from various companies, spread over three years. This initiative is a collaborative effort involving BioWin, the Health Cluster of Wallonia and the Public Service of Wallonia, representing a significant commitment to advancing medical research and development in the region.

Sarcopenia Research Program with Revatis SA

Genflow, together with Revatis SA, has launched a 3-year sarcopenia research program, generously funded by a grant totalling 1.34 million euros. Sarcopenia, the progressive loss of muscle mass and function associated with ageing, poses a significant health risk and affects the quality of life for millions of elderly people worldwide. This collaborative effort aims to expand and diversify Genflow's research pipeline, addressing this growing concern as the global population ages. The partnership will leverage both companies' expertise to develop innovative solutions and contribute valuable insights into the mechanisms of age-related muscle deterioration.

mRNA Delivery Research with EXO Biologics

Genflow and EXO Biologics have initiated a 3-year scientific program, supported by a grant of 1.55 million euros. The project focuses on the development of a novel mRNA delivery system using exosomes to encapsulate and transport Genflow's proprietary centenarian SIRT6 gene. This cutting-edge approach aims to harness the natural advantages of exosomes, such as enhanced stability, improved cellular uptake, reduced immunogenicity, minimal toxicity, natural cargo sorting and reduced off-target effects, among others. This endeavour not only demonstrates Genflow's momentum in leading-edge research, but also holds the potential to revolutionize therapeutic interventions for Werner Syndrome, an accelerated ageing condition and holds great promised for a range of other age-related conditions.

Dr. Eric Leire, CEO of Genflow commented: *"We are excited to embark on this exciting new research, which aligns with our quest to understand and alleviate the impacts of ageing. Launching both of these programs represents a strategic move to enhance our research capabilities, while contributing to the understanding of age-related conditions. Both of these strategic initiatives will strengthen Genflow's position at the forefront of ageing-related research, and its mission to improve the health and well-being of older adults."*

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For further information please contact:

Genflow Biosciences Plc	
Dr Eric Leire Chief Executive Officer	+32 477 495 881
Clear Capital Markets	
Joint Corporate Broker Bob Roberts	+44 203 869 6080
Capital Plus Partners Ltd	
Joint Corporate Brokers Dominic Berger Keith Swann Jon Critchley	+44 203 821 6167 +44 0203 821 6169 +44 0203 821 6168
Harbor Access	
Investor Relations Jonathan Paterson	+1-475-477-9401

About Genflow Biosciences

Established in 2020, Genflow Biosciences Ltd is a UK-based biotechnology company, with R&D facilities in Belgium, developing and researching potential novel therapeutics that halt or slow the ageing process enabling society to live longer, healthier lives. Genflow Biosciences lead compound is GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow Biosciences expects to commence a clinical trial in 2024 to study the potential benefit of GF-1002 in non-alcoholic steatohepatitis (NASH) for which there are few or no-approved therapies. By treating ageing as a risk factor to disease, Genflow Biosciences aims to reduce the financial, emotional, and social costs of an ageing population.

For more information: www.genflowbio.com

About Revatis SA

Revatis SA is a biotechnology firm based in Luxembourg specializing in the collection, production and storage of autologous muscle-derived mesenchymal stem cells (MdmSC) for immediate therapeutic use or storage for further processing. RevaTis technology is minimally invasive and offers benefits for generating a large number of autologous stem cells. Their expertise in sarcopenia research makes them a valuable partner in addressing muscle deterioration in the elderly.

For more information: www.revatis.com

About EXO Biologics

EXO Biologics is Belgian biotech company committed to developing biopharmaceuticals using Extracellular Vesicles (EVs). Their work in mRNA encapsulation and delivery is revolutionizing the approach to genetic and cellular therapies.

For more information: www.exobio.be

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDGZGMMZRZGDZM